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Ovarian cancer is the ﬁfth largest cancer killer in women. Improved understanding of the molecular pathways implicated in the
pathogenesis of ovarian cancer has led to the investigation of novel targeted therapies. Ovarian cancer is characterized by an
imbalancebetweenpro-andantiangiogenicfactorsinfavorofangiogenesisactivation.Variousantivascularstrategiesarecurrently
under investigation in ovarian cancer. They can schematically be divided into antiangiogenic and vascular-disrupting therapies.
This paper provides a comprehensive review of these new treatments targeting the tumor vasculature in this disease. Promising
activities have been detected in phase II trials, and results of phase III clinical trials are awaited eagerly.
1.Introduction
Ovarian cancer is the ﬁfth largest cancer killer in women.
Primary surgical cytoreduction followed by platinum-based
chemotherapy is the standard treatment for patients with
advanced epithelial ovarian cancer. However, despite this
aggressive approach, all stages combined, the 5-year survival
rate remains only around 45% [1]. Novel approaches to
improve disease outcome are thus urgently needed.
There is a strong rationale to use antivascular therapies
in epithelial ovarian cancer. Ovarian cancer is characterized
by an imbalance between pro- and antiangiogenic factors
in favor of angiogenesis activation, with an increase in
the tumor levels of proangiogenic factors (i.e., vascular
endothelial growth factor (VEGF), ﬁbroblast growth factor
(FGF), platelet-derived growth factors (PDGFs), tumor
necrosisfactor(TNF)-alpha,angiopoietins,interleukin(IL-6
and IL-8, etc.) and a decrease in anti-angiogenic factors (i.e.,
angiostatins, endostatins, etc.) [2]. Angiogenesis is necessary
for tumors to grow beyond a few millimeters and is triggered
by tumor hypoxia that induces the release of pro-angiogenic
factors [3]. Angiogenesis has also an important role in the
formation of ascites, a frequent clinical feature of advanced
ovarian cancer. The accumulation of ascites results mainly
from the increased permeability of the peritoneal capillaries.
VEGF,alsoknownasthe“vascularpermeabilityfactor,”plays
a key role in this process [4] (see Figures 1 and 2).
Various antivascular strategies have been investigated
in ovarian cancer. They can schematically be divided into
antiangiogenic therapies and vascular-disrupting therapies.
Given the important role of vascular biology in ovarian can-
cer, it is not surprising that these new treatment approaches
have shown promising activity in this disease, even when
administered as a single agent.
2. Antiangiogenic Therapies
2.1. VEGF. The most studied antiangiogenic strategies tar-
get the VEGF/VEGF receptor (VEGFR) pathway through
inhibition of its ligands and/or receptors. The VEGF family
includes 6 glycoproteins (VEGF-A to E and placental growth
factor) and 3 tyrosine kinase receptors (VEGFR1 to 3).
VEGF-A promotes angiogenesis through enhancement of
permeability, activation, survival, migration, invasion, and
proliferation of endothelial cells [5]. VEGFR1 and VEGFR2
mediate the eﬀects of VEGF-A [6]. Recent studies suggest
a direct eﬀect of VEGF-A on tumor cell proliferation
the VEGFR2 via a mechanism thought to involve the2 Journal of Oncology
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Figure 1: Major pathways promoting angiogenesis in epithelial ovarian cancer. VEGF: vascular endothelial growth factor, PDGF: platelet-
derived growth factor, mTOR: mammalian target of rapamycin.
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Figure 2: Molecular events leading to increased angiogenesis in epithelial ovarian cancer. VEGF: vascular endothelial growth factor, PDGF:
platelet-derived growth factor, FGF: ﬁbroblast growth factor, TNF = tumor necrosis factor, IL: interleukin.Journal of Oncology 3
AKT/mTOR pathway [7]. VEGF-A also regulates the inva-
siveness of cancer cells by altering the expression of matrix
metalloproteinase-2 [8].
2.1.1. Agents Directed Against VEGF Ligand(S). (1) The most
widely investigated anti-VEGF ligand agent is bevacizumab
(BEV). BEV is a recombinant humanized monoclonal
antibody that binds and neutralizes all biologically active
isoforms of VEGF. Published studies are presented in this
section, while ongoing trials are summarized in Table 1.
(a) Single-Agent Activity. In 2005, Monk et al. reported an
objective response lasting more than 5 months in a patient
treated with BEV monotherapy after failing eleven lines of
chemotherapy and radiation therapies [9]. Later, the same
group found a 16% objective response rate (ORR) in a
retrospective analysis of 32 patients with refractory epithelial
ovarian cancer treated with BEV alone or in combination
with chemotherapy (after failing 2 to 10 prior cytotoxic
regimens) [10].
In the phase II GOG 170-D trial, Burger et al. reported
a partial response (PR) rate of 18% (11 out of 62) and
a complete response (CR) rate of 3% (2 out of 62) in
patientswithpersistentorrecurrentepithelialovariancancer
or primary peritoneal cancer having received 1 or 2 prior
cytotoxic regimens and treated with BEV monotherapy.
Median progression-free survival (PFS) was 4.7 months
[11]. These results were conﬁrmed by Cannistra et al. who
observed PR in 15.9% (7 out of 44) with a median PFS of 4.4
months with single-agent BEV in women with refractory or
resistant ovarian cancer or peritoneal serous cancer [12].
BEV maintenance therapy after complete response to
cisplatin-based chemotherapy is an interesting concept and
showed promising results in xenograft models of ovarian
cancer by prolonging survival [13]. This approach is cur-
rently explored in scheduled and ongoing trials (see Table 1).
(b) BEV and Chemotherapy. The vessels formed during
tumor angiogenesis are structurally and functionally abnor-
mal. This leads to an impaired tumor blood supply that
may interfere with the delivery of therapeutics. Hypoxia also
renders tumor cells more resistant to both radiation and
cytotoxic drugs [14]. It has been proposed that the “nor-
malization” of the tumor vasculature by BEV could allow
a better delivery of chemotherapy and decrease hypoxia,
making tumors more chemosensitive [15].
In a retrospective analysis of 23 patients with recurrent
platinum-refractory epithelial ovarian cancer progressing
after 2 to 15 prior cytotoxic regimens, Wright et al. obse-
rved PR in 35% with a combination of BEV associated
with various chemotherapy regimens (cyclophosphamide,
5-ﬂuorouracil, docetaxel, or gemcitabine/liposomal doxoru-
bicin). Median PFS was 5.6 months in the patients who
achieved a PR [16]. Richardson et al. reported an ORR of
78% and a median PFS of 12 months in a retrospective
analysis of 35 patients with recurrent ovarian cancer treated
with a combination of gemcitabine, cisplatin or carboplatin
and BEV. The higher ORR observed in this last study could
be explained by the inclusion of a vast majority of platinum-
sensitive patients [17]. Cohn et al. retrospectively identiﬁed
10 patients with advanced, recurrent and refractory ovarian
cancer who were treated with a combination of BEV and
weekly taxane (paclitaxel or docetaxel) after failure of 1 to
4 prior chemotherapy regimens. The 5 symptomatic patients
inthisstudyexperiencedarapidsubjectivepalliationofpain,
nausea, and ascites [18].
Metronomic administration of chemotherapy, deﬁned as
the frequent administration of doses substantially lower than
the maximum tolerated dose, can suppress tumor growth,
probably through stimulation of the release of throm-
bospondin 1, a potent and endothelial-speciﬁc inhibitor
of angiogenesis [19]. Shortening the time between cycles
provides more sustained apoptosis of endothelial cells within
the tumor vascular bed [20]. Metronomic chemotherapy
regimens deliver lower doses of cytotoxic agents, thereby
decreasing potential side eﬀects and improving patient
tolerance [21]. In a retrospective analysis, 15 heavily pre-
treated patients with recurrent ovarian cancer (5–15 prior
chemotherapy regimens) received a combination of BEV
and metronomic oral cyclophosphamide with encouraging
results: CR 13.3% and PR 40% [22]. However, in a prospec-
tive phase II trial that included 70 less heavily pretreated
patients with recurrent ovarian cancer, combination of BEV
withmetronomiccyclophosphamideshowedPRinonly24%
with a median PFS of 7.2 months [23].
Various combinations of BEV and chemotherapy are
currently being tested; these studies are brieﬂy described in
Table 1.
(c) BEV and Other Targeted Therapies. Combination therapy
in this context can be divided into horizontal and verti-
cal molecular pathway blockade. The horizontal approach
involves the association of targeted agents to inhibit two or
more diﬀerent pathways simultaneously, while the vertical
approach involves the inhibition of various molecular steps
of the same pathway, thus counteracting negative feedback
loops. By inhibiting the activation of alternate molecular
pathways, these combinations could theoretically decrease
treatment resistance [24].
Epithelial growth factor receptor (EGFR) is overex-
pressed in up to 70% of advanced epithelial ovarian cancers
[25] and an increased level of EGFR expression has been
correlated with poorer overall survival [26]. The VEGF and
the EGFR pathways are interconnected: VEGF signaling is
upregulated by EGFR expression and VEGF upregulation
independent of EGFR signaling seems to contribute to
resistance to EGFR inhibition [27]. Since EGFR inhibitors
alonehaveshownlimited activityinepithelial ovarian cancer
[28, 29], it was postulated that combining an EGFR tyrosine
kinase inhibitor like erlotinib with BEV might improve
response rates. Unfortunately, in a phase II trial conducted
in 13 patients with recurrent ovarian cancer treated with a
combination of BEV and erlotinib after failure of 1 to 3 prior
chemotherapy regimens, ORR was relatively low (15%) and
median PFS (4.1 months) did not seem to be improved over
BEV alone [30]. Other trials investigating this combination
are planned (see Table 1).4 Journal of Oncology
Table 1: Ongoing studies with bevacizumab (BEV) in ovarian cancer.
Stage of the disease Phase Intervention Trial number
Monotherapy
Recurrence after prior
therapy with
maintenance BEV
II BEV monotherapy NCT00866723
Combination with chemotherapy
Newly diagnosed III Carboplatin and paclitaxel
with versus without BEV
ICON7
NCT00483782
Previously untreated
stage III or IV III
Carboplatin and paclitaxel
versus carboplatin,
paclitaxel, and concurrent
BEV with versus without
extended BEV
GOG218
NCT00262847
Adjuvant II
Carboplatin, paclitaxel and
BEV (BEV omitted in ﬁrst
cycle)
OVCA
NCT00129727
Newly diagnosed
stage III/IV II Carboplatin, paclitaxel and
BEV
AV53206s
NCT00127920
Newly diagnosed
stage IB-IV II Oxaliplatin and docetaxel
with BEV
TEACO
NCT00296816
Newly diagnosed
stage II-III II
IV paclitaxel, IP cisplatin
and IV BEV followed by
BEV consolidation
AVF3953
NCT00511992
Initial treatment of
optimal stage II or III
(adjuvant)
II IV and IP paclitaxel, IP
cisplatin, and IV BEV
06-064
NCT00588237
Platinum-sensitive
recurrent III
Carboplatin and paclitaxel
with versus without BEV
followed by secondary
cytoreduction surgery
GOG213
NCT00565851
Platinum-sensitive
recurrent III
Carboplatin and
gemcitabine with versus
without BEV
AVF4095g
NCT00434642
Platinum-sensitive
recurrent II Gemcitabine, carboplatin
and BEV
2005CO073
NCT00267696
Platinum-sensitive
recurrent II Carboplatin and liposomal
doxorubicin plus BEV
CR015094
NCT00698451
Platinum-sensitive
recurrent II Oxaliplatin, gemcitabine,
and BEV
DF 04-356
NCT00418093
Recurrent having
failed platinum- and
taxane-based
regimens
II Pemetrexed and BEV 08-0508
NCT00868192
Platinum-resistant
recurrent II Weekly topotecan with BEV AVF3648s
NCT00343044
Platinum-resistant
recurrent II BEV and docetaxel MCC-14920
NCT00504257
Platinum-resistant
recurrent II BEV and carboplatin 2008-000878-20
NCT00744718
Platinum-resistant
recurrent II BEV and liposomal
doxorubicin
AVF3910s
NCT00846612
Platinum-resistant
recurrent II
Sequential BEV and
metronomic
cyclophosphamide
08-148
NCT00856180Journal of Oncology 5
Table 1: Continued.
Stage of the disease Phase Intervention Trial number
Monotherapy
Recurrence after prior
therapy with
maintenance BEV
II BEV monotherapy NCT00866723
Combination with chemotherapy
Platinum-resistant
recurrent II BEV and albumin-bound
paclitaxel
ALSSOPR0501
NCT00407563
2nd or later complete
remission, or
untreated or
refractory to
platinum treatment
or no response to
salvage treatment
II
Stem-cell transplant trial
evaluating treatment with
BEV plus gemcitabine,
docetaxel, melphalan, and
carboplatin
2007-0368
NCT00583622
Advanced peritoneal
carcinomatosis I IP oxaliplatin and paclitaxel
plus IV paclitaxel and BEV
2006-1068
NCT00491855
Combination with other targeted therapies
Newly diagnosed II
BEV and erlotinib as 1st
line consolidation chemo
after carboplatin, paclitaxel,
and BEV induction therapy
07-039
NCT00520013
Relapsed or refractory II BEV and erlotinib
UARIZ-05-0178-
01
NCT00696670
Recurrent or
metastatic II BEV and erlotinib NCI-6759
NCT00126542
Refractory or
recurrent II BEV and sorafenib NCI-07-C-0058
NCT00436215
Persistent or recurrent II BEV with or without
everolimus
GOG-0186G
NCT00886691
Studies were accessed from http://www.clinicaltrials.gov/ on May 17, 2009
IV = intravenous, IP = intraperitoneal
Sorafenib inhibits, among others, the VEGFR2 and Raf
kinases. In a phase I dose-escalation study with a combi-
nation of BEV and sorafenib, 6 of 13 (46%) patients with
ovarian cancer had a PR [31]. A phase II study with this
combination is ongoing (see Table 1).
Other combinations of BEV with targeted therapies have
been tested in preclinical models. Since the mammalian
target of rapamycin (mTOR) pathway regulates VEGF
expression in cancer cells [32], researchers combined BEV
and rapamycin in an ovarian cancer xenograft model and
f o u n da9 4 %r e d u c t i o ni nt u m o rg r o w t ha sw e l la sap r o -
longed survival [33]. Everolimus, another mTOR inhibitor,
is now under investigation in a randomized phase II trial (see
Table 1).
(d) Toxicities of BEV. Angiogenesis inhibitors are not easy
drugs to manipulate with some speciﬁc toxicities. Common
complications following treatment with BEV in colorectal
cancer, where this drug is widely used, include hypertension
(25% grade 1-2, 5% grade 3-4), proteinuria (9% grade 1-
2, 1% grade 3-4), bleeding (28% grade 1-2, 3% grade 3-
4), wound-healing complications (3% grade 1-2, 1% grade
3-4), arterial thrombo-embolic events (1.5%, mostly grade
3-4), and gastrointestinal (GI) perforations (2%, mostly
grade 3-4, with only 0.4% grade 5) [34]. The complication
rate in ovarian cancer is quite similar, but there are some
noteworthy speciﬁcities. In the published phase II ovarian
studies, the rate of GI perforations varied from 0% [11]t o
11.4% [12], leading to the early closure of the latter study. It
washypothesizedthattheincreasedrateofbowelperforation
in the latter study was due to the fact that these patients
were more heavily pretreated, but this ﬁnding could not
be conﬁrmed in other studies. Intestinal obstruction and
bowel wall involvement by the tumor were other potential
risk factors, but they were not statistically signiﬁcant. In a
retrospective review of 62 patients treated with BEV after a
medianof5priorchemotherapyregimens,researchersfound
grade 3–5 toxicities in 24% of patients, including grade 3-
4 hypertension in 7%, GI perforations in 7%, and chylous
ascites (probably due to lymphatic disruption by targeting
VEGF-C) in 5%. Development of GI perforations and chy-
lous ascites appeared to correlate with tumor response [35].
There is a trend towards increased toxicity when BEV is
combined with a cytotoxic agent [35]. GI perforation seems
to be more frequent in ovarian cancer than in other solid
tumors and could be favored by peritoneal carcinomatosis.6 Journal of Oncology
In a retrospective cohort of patients without clinical symp-
toms of bowel obstruction and without evidence of bowel
involvement, there were no cases of GI perforation or other
grade 3/4 toxicities [36]. Careful patient selection might
reduce the risk of GI perforations but all toxicities will not
be avoided. Researchers recently reported two cases of GI
perforations in a retrospective analysis of 35 patients treated
with gemcitabine, platinum, and BEV. These patients had
noneoftheabovementionedriskfactorsandwerenotheavily
pretreated [17]. It seems in any case preferable to withhold
therapy for at least 30 days before surgery [37].
Rare complications reported speciﬁcally in ovarian can-
cer patients treated with BEV include spontaneous nasal
septal perforation [38] and erosive osteoarthritis [39].
(2) Aﬂibercept (VEGF-trap) is a VEGF-ligand-binding
antiangiogenic agent that binds and inactivates VEGF-B
and placental growth factor in addition to VEGF-A. In
preclinical models of ovarian cancer, it signiﬁcantly reduced
both tumor burden and ascites [40, 41]. A phase I trial of
VEGF-trap in patients with advanced solid tumors included
one patient with ovarian cancer. This patient experienced
a PR. Fatigue (9 out of 10 patients), pain (4 out of 10
patients), and constipation (4 out of 10 patients) were the
most common side eﬀects of this new drug [42]. In a phase
II trial of VEGF-trap in patients with platinum-resistant and
topotecan and/or liposomal doxorubicin-resistant advanced
ovarian cancer [43] an interim analysis after accrual of 162
patients showed that 11% of the patients receiving the study
drug experienced a PR [44]. A phase II trial of VEGF-
trap in advanced ovarian cancer patients with recurrent
symptomatic malignant ascites [45]h a sb e e nc o m p l e t e db u t
not yet reported. A phase II trial combining VEGF-trap with
docetaxel in patients with persistent or recurrent ovarian
epithelial cancer is currently ongoing [46].
(3) HuMV833 is another monoclonal antibody directed
against VEGF. In a phase I study conducted in patients
with advanced cancer, one patient with ovarian cancer
experienced a PR that lasted 9 months [47].
2.1.2. VEGFR Tyrosine Kinase Inhibitors. Cediranib (AZD
2171, CED) is a highly selective and potent oral tyrosine
kinase inhibitor (TKI) of VEGFR1, VEGFR2, VEGFR3, and
c-Kit. In a phase II study conducted in recurrent epithelial
ovarian cancer, researchers found CED to have an ORR of
18.5%. Grade 3 toxicities included hypertension (13 out
of 27 patients), fatigue (5 out of 27 patients), diarrhea
(3 out of 27 patients), vomiting (2 out of 27 patients),
hyponatremia (2 out of 27 patients), oral cavity pain (2 out
of 27 patients), and nausea, constipation, abdominal pain,
headache, and hypothyroidism (1 out of 27 patients). Grade
4 toxicities included central nervous system hemorrhage (1
outof27patients),lipaseelevation(1outof27patients),and
hypertriglyceridemia(1outof27patients)[48].TwophaseII
trials are currently studying CED in recurrent ovarian cancer
[49, 50], while a phase III randomized study is comparing
chemotherapy with carboplatin and paclitaxel (PBC) versus
concurrent CED and PBC versus concurrent CED and PBC
followed by maintenance CED in women with platinum-
sensitive relapsing ovarian epithelial carcinoma [51].
Ramucirumab (IMC-1121B) is a fully human antibody
that blocks the interaction between VEGF and VEGFR2,
resulting in potent inhibition of an array of biological
activities of VEGF, including activation of the receptor and
its signaling pathway, intracellularcalciummobilization, and
migration and proliferation of endothelial cells [52]. It is
currently under study in a phase II trial of persistent or
recurrent epithelial ovarian carcinoma [53].
Semaxinib (SU5416) is a tyrosine kinase inhibitor with
activity against VEGFR2. It reduced microvessel density and
tumor growth in a preclinical tumor model with high VEGF
expression [54].
Despite these promising data, some combination trials
resulted in very disappointing results. In a recent preclinical
study of metronomic paclitaxel with the VEGFR2 inhibitor
SU5416, researchers found that the combination therapy
showed an additive eﬀect in tumors with low VEGF
expression, while they observed an antagonism in tumors
with high VEGF expression. They postulated that the lack
of additive eﬀect between these 2 drugs in tumors with
high VEGF expression might be due to the fact that these
two agents acted through the same pathways, and that
their concomitant use could not produce more eﬀects than
each drug used in monotherapy [54]. These experiments
outline that a better knowledge of the various molecular
pathways implicated will help us to investigate the optimal
combination partners and schedules.
2.2. PDGF. Platelet-derived growth factor (PDGF) is a
potent mitogen and chemotactic factor for a variety of
mesenchymal cells, such as ﬁbroblasts and vascular smooth
muscle cells. They exert their eﬀects on target cells by
activating two structurally related protein tyrosine-kinase
receptors, α and β located on pericytes [55]. High expression
of PDGF receptors is a common characteristic of solid
tumors [56].
PDGF is expressed in 73% of ovarian carcinomas,
while 36% express PDGF-receptor alpha (PDGFRA). In
addition, overexpression of PDGFRA is an independent
poor prognostic factor in ovarian carcinoma [57]. Imatinib
mesylate is a small molecule that inhibits the tyrosine kinases
abl, c-kit, PDGFRA, and PDGFRB. It inhibits the growth
of ovarian cancer cells through PDGFRA inactivation [58],
and decreases the secretion of VEGF by epithelial ovarian
cancer cells [59]. However, in the clinical setting, imatinib
has failed to show relevant clinical activity as a single agent.
There was no complete or partial response with imatinib
monotherapy in a phase II trial that enrolled 16 patients with
platinum/taxane-resistant disease overexpressing at least one
imatinib molecular target [60]. In another phase II trial
with imatinib in a less pretreated ovarian cancer population,
median PFS was also disappointingly low: 2 months [61].
There are various reasons for the ineﬀectiveness of imatinib
monotherapy in ovarian cancer: downregulation of c-kit
and PDGFR may lead to induction of VEGF, inhibition
of a single tyrosine kinase might be insuﬃcient to impact
downstream signaling cascades, and the molecular targets of
imatinib might not be relevant in the occurrence of ovarianJournal of Oncology 7
cancer in comparison with gastrointestinal stromal tumor or
chronic myeloid leukemia where a single speciﬁc mutation
or a translocation, respectively, can be responsible for the
genesis of these two cancers [62]. Despite these results, a
phase II study of imatinib monotherapy in patients with
recurrent platinum and taxane-resistant epithelial ovarian
cancer whose tumor expresses either c-kit, PDGFR, or ABL
is currently accruing patients [63].
By dysregulating proangiogenic signaling, there was
some hope that the use of imatinib in a combination
a p p r o a c hm i g h tb em o r ee ﬀective. This was supported
by a preclinical model of human ovarian carcinoma in
which combination treatment with imatinib and paclitaxel
induced increased apoptosis of tumor-associated endothelial
cells, which resulted in a reduced tumor burden [64].
However, combination therapy with imatinib and docetaxel
in 23 heavily pretreated patients with advanced, platinum-
resistant ovarian cancer, and primary peritoneal carcino-
matosis resulted in a disappointing ORR of 21.7% (1 CR
and 4 PR) and a median PFS of 1.8 months [65]. A phase
II study is currently studying the combination of paclitaxel
with imatinib in taxane-pretreated ovarian cancer [66].
2.3. Multitargeted Tyrosine Kinase Inhibitors. Targeting the
PDGF/PDGFR axis alone or in combination with classical
chemotherapy is not very eﬀective in the clinical setting.
Endothelium homeostasis is regulated to a large extent by
the PDGF/PDGFR system expressed by pericytes. Pericytes
are perivascular cells that provide local survival signals
for endothelial cells. Combination approaches targeting the
VEGF/VEGFR and the PDGF/PDGFR axes are thus very
appealing [67].
Sunitinib (SUN) is an orally bioavailable small molecule
thatinhibitsmultipletyrosinekinasesincludingallthePDGF
receptors and VEGF receptors, as well as c-kit, RET, CSF-
1R, and ﬂt-3. A patient with recurrent clear cell ovarian
carcinoma brieﬂy responded to SUN as ﬁfth-line therapy
[68]. At least three phase II trials of SUN in recurrent
and refractory ovarian carcinoma are currently ongoing (see
Table 2). Typical side eﬀects of SUN in other diseases are
fatigue(28%grade2-3),diarrhea(20%grade2-3),dyspepsia
(16% grade 2-3), hypertension (16% grade 2-3), hand-foot
syndrome (15% grade 2-3), nausea (13% grade 2), stomatitis
(13% grade 2-3), anorexia (12% grade 2-3), neutropenia
(40% grade 2-3, 2% grade 4), thrombocytopenia (21% grade
2-3), lipase elevations (25% grade 2-3, 3% grade 4) [69], and
hypothyroidism (53–85%) [70].
Sorafenib (SOR) is an oral small molecule that pre-
dominantly inhibits the serine/threonine raf-1 kinase. The
moleculealsoinhibits othertyrosinekinasereceptorsinclud-
ing VEGFR1, VEGFR2, VEGFR3, PDGFRB, ﬂt-3, and c-kit.
The Ras/raf/MEK kinase pathway plays a key role in cellular
proliferation. In addition, the Raf kinase is a downstream
modulator of the VEGF signaling pathway [71]. Oncogenic
b-raf mutations have been found with high frequency in
ovarian cancer [72, 73]. After encouraging phase I results,
where about 50% of patients with epithelial ovarian cancer
had evidence of stable disease [74], SOR is now being tested
in various combinations (see Table 2).
Vatalanib is a multitargeted tyrosine kinase inhibitor
targeting angiogenesis that inhibits PDGFRB, VEGFR1,
VEGFR2, c-Kit, and c-Fms. In a preclinical model of VEGF-
dependent human ovarian carcinomas, vatalanib inhibited
the formation of malignant ascites and the tumor growth
[75, 76]. It is currently under investigation in advanced solid
tumors.
BIBF 1200 is a combined inhibitor of PDGFR, VEGFR,
and FGFR [77]. It was tested as maintenance therapy in a
phase II randomized double-blind trial in ovarian cancer
patients who responded to their last (at least second line)
chemotherapy. Median time to RECIST progression was 4.8
months for BIBF 1120, and 2.8 months for placebo. Grade 3
and4adverseeventswereseenin54and7%(BIBF1120)and
25 and 3% (placebo) of patients. The rate of gastrointestinal
toxicities was slightly higher in the BIBF 1120 arm (16 versus
10%, all grade 3; no grade 4 events). Elevation of liver
enzymesoccurredin43%(BIBF1120)versus6.3%(placebo)
[78]. Other multitargeted tyrosine kinase inhibitors currently
under investigation are summarized in Table 2.
2.4. Endothelin. The endothelin axis comprises 3 small
peptides (ET-1 to -3) that mediate various physiological
processes by binding to endothelin A (ETA) and endothelin
B( E T B) surface receptors. Activation of the ETA receptor
(ETAR) by ET-1 increases tumor cell proliferation, survival,
angiogenesis, migration, invasion, and metastasis in ovar-
ian cancer [79]. Endothelins also modulate angiogenesis
indirectly, as VEGF and ET-1 have reciprocal stimulatory
interactions in vivo [80]. More than 90% of primary ovarian
cancers express ET-1, and ET-1 expression in tumors is
signiﬁcantly elevated compared to normal ovarian tissue.
Moreover, the vast majority of ovarian carcinomas express
the ETAR[ 81], which is emerging as an attractive target for
anti-angiogenesis therapy.
Atrasentan is a selective ETAR antagonist. In ovarian
carcinoma xenografts, atrasentan signiﬁcantly reduced mic-
rovessel density, expression of VEGF, matrix metallo-
proteinase-2, and increased the percentage of apoptotic
tumor cells. Combined treatment with atrasentan and pacli-
taxel produced additive antitumor, apoptotic, and antiangio-
genic eﬀects [82].
In humans, the most common side eﬀects of atrasentan
include fatigue, edema, and rhinitis [83].
In a preclinical model, ZD4054, another selective ETAR
antagonist, signiﬁcantly reduced tumor growth and angio-
genesis [84]. The reduction in new vessel formation was
even more pronounced when ZD4054 was combined with
geﬁtinib[85].Asisthecasewithatrasentan,thecombination
of ZD4054 with paclitaxel also produced additive antitumor
eﬀects [86].
2.5.mTORInhibitors. Inhibition ofmTORreducessecretion
of VEGF by the tumor through inhibition of HIF-1α.I n
addition, mTOR inhibitors can also decrease cancer cell
proliferationandsurvival[87].RAD001(everolimus)dimin-
ished the expression of VEGF and inhibited angiogenesis in
a transgenic mouse model of ovarian cancer [88]. RAD001
signiﬁcantly enhanced cisplatin-induced apoptosis in vitro8 Journal of Oncology
Table 2: Ongoing trials with multitargeted tyrosine kinase inhibitors in ovarian cancer.
Agent Targets Phase Intervention Stage of the
disease Trial number
Sunitinib
VEGFR
PDGFR
c-kit
RET
CSF-1R
ﬂt-3
II Sunitinib
monotherapy
Platinum-
resistant
recurrent
AGO-OVAR 2.11
NCT00543049
(Germany)
II Sunitinib
monotherapy
Recurrent or
refractory
DF08-056
NCT00768144
(United States)
II Sunitinib
monotherapy
Advanced
and/or
metastatic
CAN-NCIC-IND185
NCT00388037
(Canada)
Sorafenib
Raf-1
VEGFR
PDGFRB
ﬂt-3
c-kit
II
Sorafenib
maintenance
versus placebo
CR after
standard
platinum
therapy
NCT00791778
II
Paclitaxel and
carboplatin +/−
sorafenib
1st line SCRI GYN 19
NCT00390611
II
Paclitaxel and
carboplatin +/−
sorafenib
Platinum-
sensitive
recurrent
CASE-CWRU-2804
NCT00096200
II Topotecan +
sorafenib
Platinum-
resistant
recurrent
GYN06-111
NCT00526799
Pazopanib
VEGFR
PDGFR
c-kit
III
Pazopanib
maintenance
versus placebo
After 1st line
chemo
AGO-OVAR16
NCT00866697
II Pazopanib
monotherapy Recurrent VEG104450
NCT00281632
I
Metronomic
topotecan +
pazopanib
Persistent or
recurrent NCT00800345
XL999
VEGFR
PDGFR
FGFR
ﬂt-3
Src
II XL999
monotherapy Recurrent NCT00277290
Motesanib
VEGFR
PDGFR
c-kit
II Motesanib
monotherapy
Persistent or
recurrent NCT00574951
Vandetanib VEGFR
EGFR
II Docetaxel
+/−vandetanib
Persistent or
recurrent
SWOG-S0904
NCT00872989
I/II
Pegliposomal
doxorubicin
+/− vandetanib
Platinum-
refractory
recurrent
NCT00862836
Studies were accessed from http://www.clinicaltrials.gov/ on May 17, 2009
VEGFR = vascular endothelial growth factor receptor, PDGFR = platelet-derived growth factor receptor,
[89]. A randomized phase II study of BEV with or without
everolimus in patients with recurrent or persistent ovarian
epithelial cancer is ongoing [90].
2.6. Src Inhibition. Src plays a critical role in tumor angio-
genesis, probably through the regulation of IL-8, an impor-
tant angiogenic cytokine [91–93]. It is also essential for the
hypoxia-mediated induction of VEGF [94]. Src inhibition
through a novel small-molecule inhibitor, AP23994, alone
orincombinationwithcytotoxicchemotherapy,signiﬁcantly
reduced tumor growth in ovarian cancer models [95]. Src is
thus emerging as a new target for antiangiogenic treatment
of ovarian cancer. A phase I trial of a Src kinase inhibitor,
dasatinib, in combination with paclitaxel and carboplatin
in patients with advanced or recurrent ovarian cancer is
currently ongoing [96]. Src inhibition is also being evaluatedJournal of Oncology 9
in a phase I study combining dasatinib and BEV in patients
with metastatic or unresectable solid tumors [97].
AZD0530 is a dual inhibitor of Src and abl. It is currently
in phase II study in combination with carboplatin plus
paclitaxel in platinum-sensitive ovarian cancer patients [98].
EphA2 is a protein overexpressed by many tumor cells.
Use of an agonistic antibody of EphA2 (EA5) in combination
with paclitaxel substantially reduced tumor growth in an
ovarian cancer model, including a paclitaxel-resistant model.
EA5 led to dissociation of Src from EphA2, resulting in
decreased phosphorylation of Src and thus VEGF expression
[99].
2.7.Integrinα5β1Targeting. EndostatinisaCOOH-terminal
fragment of collagen XVIII and is a potent angiogenesis
inhibitor. Integrin α5β1 is the major target for endostatin-
mediated inhibition of endothelial cell proliferation and
migration. Endostatin was shown to block peritoneal attach-
ment and vessel cooption by ovarian cancer cells [100].
It is currently being investigated in phase I studies in
advanced refractory solid tumors [101, 102]. Volociximab
is a chimeric monoclonal antibody that blocks α5β1 bind-
ing to ﬁbronectin and induces apoptosis in proliferating
endothelial cells. It was tested in a phase I/II study in
combination with pegylated doxorubicin in patients with
recurrent platinum-resistant ovarian cancer. Since a pre-
liminary analysis of PFS suggested that there was a low
probability of detecting a statistically signiﬁcant diﬀerence in
favor of the combination regimen, the study was closed to
enrollment [103].
2.8. Thalidomide (THAL). Multiple mechanisms of action
have been proposed for THAL. It could, at least in part,
act through an antiangiogenic eﬀect, by inhibiting tumor-
necrosisalpha,VEGFand/orﬁbroblastgrowthfactor2[104].
In a phase I study involving 17 heavily pretreated patients
with recurrent epithelial ovarian cancer, 18% experienced
a PR and 35% a stable disease after 6 months. Median
time to progression was 10 months. Common grade 1 or 2
side eﬀects included constipation (76%), neuropathy (71%)
and fatigue (65%). Among the 5 grade 3/4 toxicities, 2
patients (12%) had a venous thrombosis [105]. A single-
institution prospective cohort study conducted in patients
with recurrent ovarian or primary peritoneal cancer who
had received a minimum of 2 prior therapeutic regimens
compared any standard intravenous chemotherapy to THAL
or treatment holiday. There was a trend towards comparable
responses in the chemotherapy and THAL arms. There was a
high rate of grade 3 dyspnea, with 8 out of 18 (44%) patients
who presented subjective shortness of breath at rest in the
THAL arm. At least one of these patients had pulmonary
embolus, a dreaded complication of THAL [106]. In a
randomized phase 2 trial comparing topotecan to topotecan
plus THAL in 75 women with recurrent epithelial ovarian
cancer, the addition of THAL to topotecan appeared to
improve response rates: ORR was 47% in the THAL arm
versus 21% in the topotecan alone arm. Median PFS was
6 months in the THAL arm compared to 4 months in the
control arm [107]. A randomized phase II study is currently
comparing carboplatin and THAL with carboplatin alone in
patients with stage Ic-IV ovarian cancer [108].
2.9. Prostaglandin E2 (PGE2). PGE2 enhances angiogenesis
through the induction of VEGF [109]. Cloﬁbric acid is
a peroxysome proliferator-activated receptor α (PPARα)
ligand that reduces PGE2 levels, leading to repression of
VEGF expression, inhibition of angiogenesis and tumor
cell apoptosis in a preclinical ovarian cancer model
[110]. In a preclinical ovarian cancer model, celecoxib,
a cyclooxygenase-2 (COX-2) inhibitor, and ciglitazone,
aP P A R γ ligand, reduced tumor growth by decreasing
angiogenesis through inhibited VEGF production in relation
to PGE2 reduction [111]. Ongoing trials are investigating
celecoxib in advanced ovarian cancer; one phase II study
is combining paclitaxel with celecoxib [112] and another
randomized phase II study is comparing cyclophosphamide
with or without celecoxib [113].
2.10. Antiangiogenic Gene Therapy. (i) Phosphatase and
tensin homologue on chromosome 10 (PTEN) is a cancer
suppressor gene. Overexpression of the PTEN gene by
transfection in ovarian cancer cell lines without PTEN
mutations leads to decreased VEGF concentrations and a
reduced number of new blood vessels. PTEN gene therapy
in murine models of human ovarian cancer suppresses
intraperitoneal dissemination and extends survival [114].
(ii) Increased IL-8 expression is associated with poor
clinical outcome in human ovarian carcinoma, and IL-8
gene silencing with small interfering RNAs (siRNAs) can
decrease tumor growth through antiangiogenic mechanisms
in preclinical models [115].
(iii) Ribozymes are catalytic RNA molecules that can
cleave other RNA molecules in a target-speciﬁc manner,
thereby downregulating the expression of any pathogenic
gene product. Angiozyme inhibits angiogenesis by selec-
tively downregulating VEGFR1 through targeted cleavage of
VEGFR1 mRNA [116]. After encouraging phase I testing, it
has now completed the phase II setting in renal cancer [117].
T h e r ei sas t r o n gr a t i o n a l et ot r yt h i sa p p r o a c hi no v a r i a n
cancer.
(iv) Shiga-like toxin 1 mutants Stx1W203F and Stx1R170H
have been shown in preclinical models to have antiprolifer-
ative and antiangiogenic eﬀects in murine xenograft models
of ovarian cancer. They are good candidates for gene therapy
[118].
2.11. Other Antiangiogenic Targets. (i) Squalamine is an
aminosterol that inhibits mitogen-induced proliferation and
migration of endothelial cells in vitro and causes signiﬁcant
in vivo inhibition of angiogenesis [119]. It is currently in
phase II testing in combination with carboplatin in patients
with recurrent or refractory stage III or stage IV ovarian
cancer [120].
(ii) CAI is a synthetic carboxyamidotriazole that inhibits
proliferation, invasion and metastasis, and neovasculariza-
tionbothinvitroandinvivo.InaphaseIIstudyof38heavily
pretreated patients with recurrent epithelial ovarian cancer,
median PFS was 3.6 months [121].10 Journal of Oncology
(iii) Angiopoietins are emerging as crucial regulators
of the angiogenic switch in tumors [122]. AMG 386 is a
peptibody that binds to and inhibits angiopoietin 1 and 2. It
is being investigated in a phase 1b study in combination with
either pegylated liposomal doxorubicin or topotecan in sub-
jectswithadvancedrecurrentepithelialovariancancer[123].
3.Vascular-DisruptingAgents
Tumor vessels have diﬀerent characteristics than normal
vessels. They have been found to be more tortuous, less
organized, and more leaky [124]. Vascular-disrupting agents
(VDAs) are a new class of agents that cause a pronounced
shutdown in blood ﬂow to solid tumors, resulting in
extensive tumor-cell necrosis due to lack of oxygen and
nutrients supply, while they leave the blood ﬂow in normal
tissues relatively intact [125]. Small molecules VDAs are the
major class of VDAs. They can be divided into 2 groups: the
tubulin-binding agents and the ﬂavonoids [126].
Combretastatin A-4 (CA-4), its prodrug ZD6126 and
AVE8062 (a water-soluble analog of CA-4) are tubulin-
binding agents that are structurally related to the colchicines
and possess potent antivascular properties [126]. CA-4 was
shown to exert its antivascular eﬀects through selective
disruption of the tubulin cytoskeleton of endothelial cells
[127]. In a murine model of ovarian carcinoma, AVE8062
eﬀectively inhibited tumor growth and was even more
eﬀective in combination with docetaxel [128]. VDAs are
currently in clinical development, alone or in combination.
5, 6-dimethyl-xanthenone-4 acetic acid (DMXAA)i sa
ﬂavonoid causing DNA damage to endothelial cells that
induces apoptosis in preclinical models [126]. When given
1–4 hours after cisplatin chemotherapy, DMXAA or CA-4
induced a markedly increased tumor response in a xenograft
model of ovarian carcinoma [129].
The diﬀerences between normal and tumor vessels can
also be exploited to selectively deliver chemotherapeutic
drugs to the tumor vasculature. Peptides containing the
asparagines-glycine-arginine (NGR) motif, which binds to a
speciﬁcisoformofCD13exclusivelyfoundinangiogenicves-
sels, have been used to deliver various antitumor compounds
to the tumor vasculature [130]. Targeted liposomal doxoru-
bicin(TVT-DOX)isaformofligand-targetednanomedicine
that contains the NGR motif on its surface. In a murine
xenograft of doxorubicin-resistant ovarian cancer, it was able
to more eﬀectively kill angiogenic tumor blood vessels and
indirectly the tumor cells that these vessels support than an
untargeted formulation of doxorubicin [131].
4.Biomarkers
4.1. Classical Markers. Plasmatic CA125 concentration is
routinely used in clinical practice as a surrogate marker for
clinicalresponseofovariancancertreatment[132].However,
CA125 has not been validated in the context of targeted
therapies. The mechanism regulating the production and/or
secretion of mucin MUC16, which is recognized by the
OC125 antibody, is as yet unknown, and it could potentially
be altered by biochemical modulation of the tumor [133].
Moreover, in a phase II study of patients receiving BEV and
SOR, the authors found a poor concordance between CA125
changes and objective imaging (67% concordance) [134],
raising the question whether CA125 monitoring can be used
to monitor tumor response to antiangiogenic therapy.
Response Evaluation Criteria in Solid Tumors (RECIST)
are routinely used to assess tumor response [135]. They can
however not be considered entirely reliable in the context
of agents that reduce tumor blood ﬂow because changes in
blood ﬂow may precede changes in tumor size [136].
4.2. Markers of Angiogenesis. There is a clear correlation in
ovarian cancer between markers of angiogenesis and poor
prognosis. Increased angiogenesis can be identiﬁed in various
ways.
Microvessel density evaluated by the speciﬁc endothelial
cell marker CD34 is correlated with poor prognosis in
ovarian cancer [137, 138]. The Chalkley count with CD34
immunostainingisthemostvalidatedmethodofmicrovessel
density determination [139].
In small retrospective analyses of ovarian tumor samples
after surgery and prior to standard chemotherapy, overex-
pression of VEGF as detected by immunohistochemistry on
tumor tissue was present in up to 48% of samples and was
shown to be independently predictive of poor prognosis
[140–142]. However, in recent series of 339 primary ovarian
cancers, only 7% showed a high expression of VEGF. The
useofdiﬀerentantibodies, scoringsystems,andcutoﬀpoints
might explain the discrepancies between studies. In any case,
theselatestdatasuggestthatthebeneﬁtofanti-VEGFtherapy
might be limited to a small subset of patients [143].
Other markers of angiogenesis are currently under study.
Serum VEGF levels are independent prognostic markers in
ovarian cancer patients [144]. Genetic testing also showed
promising results, as the simultaneous carriage of 3 sin-
gle nucleotide polymorphisms associated with increased
VEGF production was shown to lead to a signiﬁcantly
impaired overall survival [145], while a 34-gene-proﬁle of
angiogenesis-related genes was able to predict the overall
survival of ovarian cancer patients [146]. Finally, high
expression of new tumor vascular markers, like STC2,
EGFL6, and FZD10, which are speciﬁcally expressed by
tumors harboring tumor endothelial cells, have been shown
to be associated with a signiﬁcant decrease in disease-free
interval [147].
Other biomarkers could be used in the future to predict
the outcome after targeted therapy. IL-8 plays a signiﬁcant
role in mediating human ovarian carcinoma-derived angio-
genesis and tumorigenesis [148], probably independently of
VEGF [149]. It was recently shown that the IL-8 A-251T
polymorphism might be a molecular predictor of response to
BEV-based chemotherapy in ovarian cancer patients [150].
pAKT may serve as a predictor of resistance to imatinib
treatment in ovarian cancer cells [151].
4.3. Imaging of Angiogenesis. New noninvasive imaging tech-
niques are currently under study. In a retrospective study of
49 women with primary ovarian cancer or metastatic tumors
to the ovary, three-dimensional power Doppler ultrasoundJournal of Oncology 11
(3D-PDU), which allows tumor vascularization assessment,
showed that vascularization was higher in advanced stage
and metastatic ovarian cancers than in early stage ovarian
cancer [152]. In a retrospective study of 41 women with
epithelial ovarian cancer, researchers found that dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI)
could help distinguish among benign, borderline, and inva-
sive tumors and was correlated with tumoral angiogenic
status, speciﬁcally the pericyte coverage index and VEGF
expression [153].
Tracers focusing on VEGF and VEGFR2 have been devel-
oped to visualize angiogenesis-related events with noninva-
sive positron emission tomography (PET) imaging [154, 155].
In preclinical murine models of ovarian carcinoma treated
with vascular-disrupting agents, [ 18F]FDG PET imaging
couldpredicttumorresponseasearlyas2hoursaftertherapy
[128].
5. Conclusion
Antiangiogenic therapy in ovarian cancer is very promising
so far, at least in phase II trials. This is probably due to
the highly angiogenesis-dependent pathophysiology of this
disease. We should however keep in mind that angiogenesis
might not be the driving force behind all cases of epithelial
ovarian cancer and that we are still missing large placebo-
controlled phase III trials that show a beneﬁt in term of
PFS or overall survival. Tools to detect the patients that are
likely to beneﬁt from antiangiogenic treatment have yet to be
validated in the clinic. This would allow us to restrict the use
of these very potent butalso onerous new drugs to those who
aremost likely to beneﬁt. A better selection of patients would
alsohelptoreducethehighcomplicationrateseenwiththese
agents, in particular GI perforations. The optimal duration
of maintenance treatment with BEV will also have to be
evaluated, and pharmaco-economic considerations will have
to be addressed. Finally, combined targeting of tumor cells,
endothelialcells,andpericytes(whichplayanimportantrole
in the stabilization of endothelial cells) is a very interesting
approach that warrants further studies.
In conclusion, antivascular treatment for epithelial ovar-
ian cancer is a very promising approach that still needs to be
validatedinthephaseIIIsetting.Asmanypatientsaspossible
should be encouraged to take part in well-designed clinical
trials.
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